| Phone | |
| Address | Talkabouturology, Russia, Nizhny Novgorod |
| Skype | ukitcom |
| Talkabouturology@list.ru |
After completion of this activity, participants will be able to:
Define the classic size criteria of clinically insignificant residual stone fragments and what may be the newer, more relevant size.
Discuss the risk of a residual kidney stone and the likelihood of outcomes including remaining asymptomatic, growth or needing further intervention.
After completion of this activity, participants will be able to:
Evaluate and characterize patients presenting with neurogenic bladder in a clinical setting.
Interpret basic urodynamic tracing of a patient with neurogenic bladder.
Counsel patients regarding the risks and benefits of the treatments for various types of neurogenic bladder.
Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options.
Describe the mechanism of action and associated side effects of the new adjuvant therapy.
Differentiate the roles between the urologist and medical oncologist in the care of patients with bladder cancer.
Discuss the opportunities for the coordination of care between the urologists and medical oncologists.
After completion of this activity, participants will be able to:
Identify basic female pelvic anatomy.
Apply the skills required for history taking in incontinent female patients.
Describe the differences between stress urinary incontinence and urgency urinary incontinence.
Describe the treatments available for stress and urgency urinary incontinence.
Describe the pathophysiology of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
Identify and implement the necessary diagnostic evaluation of the patient with BPH.
Describe indications and the evidence supporting the use of medical and surgical management options in the patient with BPH.
Apply the AUA Guidelines regarding the evaluation of patients with possible hematuria in a safe and effective manner and with appropriate resource allocation.
Counsel patients with hematuria about possible etiologies and their significance.
Describe the physiologic roles of testosterone and the symptoms of low testosterone.
Identify the health benefits of testosterone replacement therapy (TRT).
State the controversies and risks of TRT.
Describe the options for TRT and how patients should be monitored.
Identify several risk factors that contribute to kidney stone development.
Prescribe appropriate labs, testing and imaging as suggested by AUA Guidelines for medical management of kidney stones.
Identify a few kidney stone dietary risk factors.
Prescribe appropriate interventions for hypercalciuric, hypocitraturic, hyperoxaluric or hyperuricosuric patients.
Describe general dietary/lifestyle tips regarding kidney stone prevention.
Recognize the pathophysiology of erectile dysfunction.
Describe risk factors for erectile dysfunction.
Perform comprehensive workup of an erectile dysfunction patient.
Identify hypogonadism and treatment options when appropriate.
Facilitate a comprehensive discussion with the patient on erectile dysfunction treatment options and engage in shared decision-making.
Evaluate and characterize patients presenting with neurogenic bladder in a clinical setting.
Interpret basic urodynamic tracing of a patient with neurogenic bladder.
Counsel patients regarding the risks and benefits of the treatments for various types of neurogenic bladder.
Describe normal penile anatomy.
Recognize common penile anomalies to aid in the management of genitourinary tract conditions.
Distinguish potentially malignant lesions from benign conditions.
Distinguish penile anomalies that warrant acute intervention from other anomalies.
Outline definitions and risk factors for recurrent UTIs
Review guidelines for evaluation and treatment of uncomplicated recurrent UTIs
Diagnose and treat uncomplicated UTIs
Diagnose and treat catheter associated UTIs (CA-UTI)
Describe the available antibiotic and non-microbial prophylaxis strategies
Classify STD's according to clinical presentation.
Utilize the appropriate diagnostic tests based on clinical presentation in regards to STD's.
Identify the guideline approved antibiotics for each STD.
Describe the current classification system for prostatitis syndromes.
Diagnose patients suffering from prostatitis based on clinical presentation.
Utilize the UPOINT system to classify and treat men with chronic pelvic pain.
Describe and understand the epidemiology and pathophysiology of testicular cancer.
Demonstrate the proper evaluation and work-up for a testicular neoplasm.
Describe the medical and surgical management options for testicular cancer.
Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.
Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines.
Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
Describe recent developments in the medical management of advanced prostate cancer.
Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
Discuss clinical investigations in the treatment of advanced prostate cancer.
Analyze the risks and benefits of treatment for advanced prostate cancer.
Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.
Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies.
Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
Discuss optimal use of third line therapies in order to maximize clinical benefit.
Adeptly counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB
Apply basic, generally accepted urological practices for effective, high-quality patient care.
Demonstrate core knowledge of urology necessary for American Board of Urology (ABU) Qualifying (Part 1) Examination and for the ABU Knowledge Assessment.
Utilize AUA Guidelines for appropriate patient evaluation and management.
List the changes to Medicare Program for 2021.
Determine coding for the appropriate level of evaluation and management.
Code complex urological issues and multiple procedures.
Describe the relationship between encounter documentation and code selection.
Describe coding information to be used in the everyday practice.
Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC
Describe sequencing and indications for active treatment with approved agents in the management of nmCRPC
Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines
Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice
Analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer
Describe recent developments in the medical and surgical management of urology patients.
Identify new technologies for the treatment of urologic conditions.
Integrate the latest guidelines on the management of urological diseases into their practice.
Lecture: Rationale, Patient Population, and Guideline Sections Case Discussions:
Mild Post-Prostatectomy
IncontinenceStress Incontinence after Radical Prostatectomy and Adjuvant or Salvage Radiation Therapy
Incontinence in the Post-TURP patient
Recurrent incontinence with sling following salvage radiation therapy
Artificial Urinary Sphincter Failure
Questions/Answer
